Skip to search formSkip to main contentSkip to account menu

RAP-011

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ActRIIA-mIgG2aFc fusion protein

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A Zebrafish Model of 5q-Syndrome Using CRISPR/Cas9 Targeting RPS14 Reveals a p53-Independent and p53-Dependent Mechanism of Erythroid Failure.
2016
2016
RAP‐011 augments callus formation in closed fractures in rats
ACE‐011 is a bone anabolic agent generated by fusing the extracellular domain of the Activin Type 2A receptor (ActRIIA) to an IgG… 
2013
2013
RAP-011 Efficiently Rescues Erythropoiesis In Zebrafish Models Of Diamond Blackfan Anemia
Diamond Blackfan Anemia (DBA) is a bone marrow failure disorder characterized by low red blood cell count but normal levels of… 
2012
2012
Modulation of Activin Signaling by RAP-011 (ActRIIA-IgG1) Improve Anemia, Increases Hemoglobin Levels and Corrects Ineffective Erythropoiesis in β-Thalassemia
Abstract 247 Background: β-thalassemia is associated with ineffective erythropoiesis, accelerated erythroid differentiation and… 
2010
2010
Lenalidomide In Combination with the Activin Receptor Type II Murine Fc Protein RAP-011: Preclinical Rationale for a Novel Anti-Myeloma Strategy
Abstract 4075 The introduction of novel treatment strategies targeting tumor cells within their microenvironment have resulted in… 
2010
2010
RAP-011 Augments Callus Formation in Closed Rat Fractures
Introduction RAP-011 is a soluble chimeric protein consisting of extracellular domain of the Activin Type 2a receptor (ActRIIA… 
2009
2009
RAP-011, a Soluble Activin Receptor Type IIa Murine IgG-Fc Fusion Protein, Prevents Chemotherapy Induced Anemia.
Abstract 161 Anemia is a common and often severe side-effect of chemotherapy treatment that can alter treatment regimens and can… 
2009
2009
B358 SF1126, A Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequen
2009
2009
RAP-011, a soluble activin receptor type IIA IgG-Fc fusion protein, is a novel bone anabolic agent that prevents bone loss and skeletal metastases in a mouse model of metastatic breast cancer.
Abstract #1158 Breast cancer cells have a strong propensity to metastasize to bone, resulting in debilitating complications such… 
2008
2008
P51. RAP-011, a soluble activin receptor type IIA IgG-Fc-fusion protein, is a novel bone anabolic agent that prevents bone loss and skeletal metastases in a mouse model of metastatic breast cancer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)